

Jenburkt Pharmaceuticals Ltd.

Regd. Office: 93, Jayprakash Road, Andheri (West), P. O. Box. 37396, Mumbai - 400 058. • Phone: 67 603 603 (100 Lines) • Fax: 91-22-6694 3127 www.jenburkt.com

CIN No.: L24230MH1985PLCO36541

Standalone Unaudited Financial Results for the Quarter & Half Year Ended on 30/09/2014 PART-I (Rs. in Lacs except per share data)

PART-I	(Rs. in Lacs except per share data							
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended	
		30/09/14	30/06/14	30/09/13	30/09/14	30/09/13	31/03/14	
	e e			Unaudited		Audited		
1	Income from Operations							
	(a) Net Sales/Income from Operations	2222.40	1920.93	1974.87	4143.33	3678.42	7620.00	
	(b) Other Operating Income	1.95	1.72	0.78	3.67	2.15	2.45	
	Total Income from Operations (Net)	2224.35	1922.65	1975.65	4147.00	3680.57	7622.45	
2	Expenses							
	(a) Cost of Materials Consumed	763.17	545.56	623.36	1308.73	1090.31	2473.41	
	(b) Purchases of Stock in Trade	0.47	0.68	0.00	1.15	0.00	0.61	
	(c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in- Trade	-71.80	28.11	61.05	-43.69	141.10	77.07	
	(d) Employee benefits Expense	454.13	488.95	410.06	943.08	844.10	1696.57	
	(e) Depriciation and amortisation Expense	48.50	37.50	39.00	86.00	75.00	155.31	
	(f) Other Expenses	626.15	608.00	543.4	1234.15	1043.58	2223.11	
	Total Expenses	1820.62	1708.80	1676.87	3529.42	3194.09	6626.08	
3	Profit from Operations before other income, finance cost and exceptional items (1-2)	403.73	213.85	298.78	617.58	486.48	996.37	
4	Other Income	24.43	6.34	36.79	30.77	37.89	161.16	
5	Profit from Ordinary activities before finance costs and exceptional items (3+4)	428.16	220.19	335.57	648.35	524.37	1157.53	
6	Finance Cost	4.66	11.53	20.83	16.19	71.03	126.50	
7	Profit from ordinary activities after finance cost but before exceptional items (5-6)	423.50	208.66	314.74	632.16	453.34	1031.03	
8	Exceptional Income	0.00	0.16	0.90	0.16	0.90	1.85	
9	Profit / (Losss) from Ordinary activities before tax (7+8)	423.50	208.82	315.64	632.32	454.24	1032.88	
10	Tax Expense	98.75	60.00	85.00	158.75	130.00	282.25	
	Net Profit from Ordinary activities after tax (9-10)	324.75	148.82	230.64	473.57	324.24	750.63	
12	Extra ordinary items	0.00	0.00	0.00	0.00	0.00	0.00	
13	Net Profit for the period (11+12)	324.75	148.82	230.64	473.57	324.24	750.63	
	Paid-up Equity Share Capital (face value of Rs.10/- each.)	464.93	464.93	464.93	464.93	464.93	464.93	
15	Reserves and surplus	0.00	0.00	0.00	0.00	0.00	2265.73	
	Earnings per share (EPS) EPS (before & after extra ordinary items) Basic & Diluted	6.98	3.20	4.96	10.19	6.97	16.15	





Jenburkt Pharmaceuticals Ltd.

Regd. Office: 93, Jayprakash Road, Andheri (West), P. O. Box. 37396, Mumbai - 400 058. • Phone: 67 603 603 (100 Lines) • Fox: 91-22-6694 3127 www.jenburkt.com

PART-	PART- II INFORMATION FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2014.						
	5	Quarter Ended Half year Er			Ended	Year Ended	
Sr. No.	Particulars	30/09/14	30/06/14	30/09/13	30/9/14	30/09/13	31/03/14
		Unaudited					Audited
A.	Particulars of Shareholding						
1	Public shareholding						
	- Number of shares	2466223	2466923	2486458	2466223	2486458	2472690
	 Percentage of shareholding 	53.05	53.06	53.48	53.05	53.48	53.18
2	Promoters and Promoter Group						
	Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	0	0	0	0	0	0
	- Percentage of shares (as a % of the	0	0	0	0	0	0
	total shareholding of promoter and			-			
	promoter group) - Percentage of shares (as a % of the	0		0	0	0	
	total share capital of the company)	U		U	U	1 "	
	total orial o suprial or the company)				-		
	b) Non - encumbered						
	- Number of shares	2183077	2182377	2162842	2183077	2162842	2176610
	- Percentage of shares (as a % of the						
	total shareholding of the Promoter and	100.00	100.00	100.00	100.00	100.00	100.00
'	Promoter group)						
	- Percentage of shares (as a % of the	40.05	46.94	40.50	40.05	46.52	40.00
	total share capital of the company)	46.95	46.94	46.52	46.95	46.52	46.82
***************************************	Particulars		30.09.2014				
B.	INVESTOR COMPLAINTS					Mark and the second service	
	Pending at the beginning of the quarter			- I	Nil		
	Received during the quarter				4		
B 8	Disposed of during the quarter			10	4		
	Remaining unresolved at the end of the			١	Vil		
	quarter						

Notes:

- 1. The above unaudited results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 11th November, 2014.
- 2. The Limited Review of the quarterly results has been carried out by the Statutory Auditors.
- 3. Figures of previous quarters / year are re-grouped/re-arranged, wherever necessary.
- 4. The Company is dealing exclusively in pharmaceuticals formulation business segment, hence segmentwise presentation of financial result is not required.
- 5. Dividend @ Rs.5.10 (51%) per Rs.10/- paid up equity share was paid, during the quarter, amounting to Rs.2,37,11,430/.
- 6. During the half year, the company has implemented Schedule II of the Companies Act, 2013, and accordingly has computed the depreciation as prescribed by Schedule II to the Act or actual useful life of assets, whichever is lower. The carrying value of assets which has completed its depreciation period as on April 1, 2014 has been adjusted to the General Reserve. The remaining assets have been depreciated over the revised useful life and as a result higher depreciation has been recognized as charge in the Statement of Profit and Loss for half year ended September 30, 2014.



Jenburkt Pharmaceuticals Ltd.

Regd. Office: 93, Jayprakash Road, Andheri (West), P. O. Box. 37396, Mumbai - 400 058. • Phone: 67 603 603 (100 Lines) • Fax: 91-22-6694 3127 www.jenburkt.com CIN No.: L24230MH1985PLCO36541

Statement of Asset & Liabilities:

(Rs. in Lacs)

	(Rs. in Lacs)					
-	Particulars	30/09/2014	31/03/2014			
A. E	EQUITY & LIABILITIES					
	Share Holders Fund	A	91			
а	a) Share Capital	464.93	464.93			
b) Reserves & Surplus	2717.49	2265.73			
С	c) Money Received against share warrants	0.00	0.00			
	Sub-total Shareholders' fund	3182.42	2730.66			
2 8	Share application money pending allotment	0.00	0.00			
3 1/	Minority interest	0.00	0.00			
4 N	Non Current Liabilities					
а	a) Long Term Borrowings	1.90	3.61			
b) Defferred Tax Liability (Net)	98.42	119.68			
С	c) Other Long Term Liabilities	270.62	257.62			
d	l) Long Term Provisions	815.50	515.08			
	Sub total Non-current liabilities	1186.44	895.99			
5 C	Current Liabilities					
а	a) Short Term Borrowings	278.74	193.53			
b) Trade Payables	486.81	410.20			
С	c) Other Current Liabilities	603.63	400.23			
d) Short Term Provisions	180.00	576.00			
	Sub total Current liabilities	1549.18	1579.96			
1	TOTAL -EQUITY AND LIABILITIES	5918.04	5206.61			
B. A	ASSETS					
1 N	Ion Current Assets	a = 2				
а) Fixed Assets	1270.84	1357.04			
b) Non Current Investments	31.21	31.21			
С) Defferred Tax Assets (Net)	0.00	0.00			
d) Long Term Loans & Advances	0.00	0.00			
е	e) Other Non Current Assets	0.00	0.30			
	Sub total Non-current assets	1302.05	1388.55			
2 0	Current Assets					
а) Current Investments	0.00	0.00			
b) Inventories ,	711.08	650.35			
С) Trade Receivables	528.81	548.31			
d	l) Cash & Cash Equivalents	2233.17	1674.80			
е) Short Term Loans & Advances	53.20	30.89			
f)	Other Current Assests	1089.73	913.71			
	Sub total - Current assets	4615.99	3818.06			
	TOTAL ASSETS	5918.04	5206.61			

By order of the Board,

For Jenburkt Pharmaceuticals Ltd.

Place : Mumbai Date : 11/11/2014

(Ashish U. Bhuta) Chairman and Managing Director.



D.L.ARORA & Co. CHARTERED ACCOUNTANTS

9/425, BHAGYODAYA, KHER NAGAR, BANDRA [EAST], MUMBAI- 400 051. TEL: 32911248

FAX: 26474719

LIMITED REVIEW REPORT

THE BOARD OF DIRECTORS,
JENBURKT PHARMACEUTICALS LIMITED,
Nirmala Apartments,
93 J.P. Road,
Andheri – West,
Mumbai -400058.

We have reviewed the accompanying statement of unaudited financial results of JENBURKT PHARMACEUTICALS LIMITED for the quarter ended on September 30th, 2014 except for the disclosures regarding "Public share holding and Promoter and Promoter Group Share holding", which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurances as to whether the Financial Statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principals laid down in Accounting Standard 25 "Interim Financial Reporting", specified under the Companies Act, 1956 (which are deemed to be applicable as per section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which is to be disclosed, or that it contains any material misstatement.

For D.L.Arora & Co. Chartered Accountants Firm Regn No.: 100545W

Place: Mumbai.

Date: 11TH November, 2014.

Dilip Arora Proprietor M. No.: 036152

MEMBERSHIP NUMBER: 36152

\\Pc-3-pc\e\My Documents - 1\Jenburkt\JPL 13-14\Limited review report.